Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Orphazyme A/S ADR (ORPH)

Orphazyme A/S ADR (ORPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,721
  • Shares Outstanding, K 35,312
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,010 K
  • 60-Month Beta 1.68
  • Price/Sales 14.82
  • Price/Cash Flow N/A
  • Price/Book 1.12
Trade ORPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/05/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 236.49%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5101 +70.55%
on 03/14/22
1.3720 -36.59%
on 03/10/22
-0.3500 (-28.69%)
since 02/28/22
3-Month
0.5101 +70.55%
on 03/14/22
2.7500 -68.36%
on 01/03/22
-1.7900 (-67.29%)
since 12/28/21
52-Week
0.5101 +70.55%
on 03/14/22
77.7700 -98.88%
on 06/10/21
-11.5200 (-92.98%)
since 03/26/21

Most Recent Stories

More News
Dear ORPH Stock Fans, Mark Your Calendars for March 31

Orphazyme has decided to delist its American Depositary Shares

ORPH : 0.8700 (-2.25%)
Why Is Orphazyme (ORPH) Stock Up Today?

The European biotech company's stock is up 40% today on no news

ORPH : 0.8700 (-2.25%)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1000 (+5.37%)
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

AXSM : 43.44 (+8.57%)
EDIT : 19.42 (+1.41%)
KLDO : 0.0080 (unch)
ORPH : 0.8700 (-2.25%)
First Week of July 15th Options Trading For Orphazyme (ORPH)

Investors in Orphazyme A/S saw new options become available this week, for the July 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...

ORPH : 0.8700 (-2.25%)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1000 (+5.37%)
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ORPH : 0.8700 (-2.25%)
CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

IBRX : 4.49 (+6.15%)
ORPH : 0.8700 (-2.25%)
CYTR : 0.1000 (+5.37%)
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1000 (+5.37%)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers

/PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq...

ONCY : 1.2300 (-1.44%)
SESN : 0.7313 (+0.16%)
CRXT : 0.3033 (+3.55%)
ORPH : 0.8700 (-2.25%)
JNJ : 171.11 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Orphazyme A/S is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company's product candidate includes Niemann-Pick disease Type C, Amyotrophic Lateral Sclerosis, sporadic Inclusion Body Myositis and Gaucher...

See More

Key Turning Points

3rd Resistance Point 1.0476
2nd Resistance Point 1.0023
1st Resistance Point 0.9362
Last Price 0.8700
1st Support Level 0.8248
2nd Support Level 0.7795
3rd Support Level 0.7134

See More

52-Week High 77.7700
Fibonacci 61.8% 48.2567
Fibonacci 50% 39.1400
Fibonacci 38.2% 30.0234
Last Price 0.8700
52-Week Low 0.5101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar